| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2022 | May 3, 2022 | Tempest Therapeutics, Inc. | Director | Buy | 100.0 | +2,118,644 | 100.00% | ✗ | $5M |
| Oct 20, 2020 | Oct 20, 2020 | Aligos Therapeutics, Inc. | Director | Buy | 100.0 | +200,000 | 30.19% | ✗ | $3M |
| Mar 3, 2020 | Mar 3, 2020 | Passage BIO, Inc. | Director | Buy | 100.0 | +225,000 | 31.76% | ✗ | $4.1M |
| Mar 3, 2020 | Mar 3, 2020 | Passage BIO, Inc. | Director | Buy | 100.0 | +225,000 | 31.76% | ✗ | $4.1M |
| May 15, 2018 | May 17, 2018 | CRISPR Therapeutics AG | Director | Sell | 17.5 | -44,000 | -6.38% | ✗ | $2.6M |
| May 7, 2018 | May 9, 2018 | CRISPR Therapeutics AG | Director | Sell | 31.3 | -121,362 | -4.26% | ✓ | $6.1M |
| Apr 30, 2018 | May 2, 2018 | CRISPR Therapeutics AG | Director | Sell | 36.3 | -30,566 | -2.02% | ✓ | $1.5M |
| Apr 26, 2018 | Apr 30, 2018 | CRISPR Therapeutics AG | Director | Sell | 25.0 | -222,258 | -6.84% | ✓ | $11.1M |
| Apr 24, 2018 | Apr 26, 2018 | CRISPR Therapeutics AG | Director | Sell | 40.0 | -22,841 | -1.30% | ✓ | $1.2M |
| Apr 20, 2018 | Apr 24, 2018 | CRISPR Therapeutics AG | Director | Sell | 18.8 | -599,671 | -12.75% | ✓ | $5.2M |
| Dec 22, 2017 | Dec 27, 2017 | CRISPR Therapeutics AG | Director | Sell | 10.0 | -3,059 | -38.15% | ✓ | $62.1K |
| Nov 24, 2017 | Nov 28, 2017 | CRISPR Therapeutics AG | Director | Sell | 23.8 | -1,900 | -19.16% | ✓ | $38.4K |
| Oct 24, 2016 | Dec 23, 2016 | CRISPR Therapeutics AG | Director | Buy | 87.5 | +161,000 | 2.44% | ✗ | $2.3M |